Search

Displaying results 6981 - 6990 of 10000 in total
  1. Drug

    Fisogatinib

    go.drugbank.com/drugs/DB16167
    Investigational

    Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).

  2. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling. … WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical

    Salts: WIN 55212-2 mesylate
  3. Drug

    Tyrosinase

    go.drugbank.com/drugs/DB16626
    Investigational

    [A231829, A231834, A231839] Within mammals, tyrosinase is found specifically in melanocytes in a glycosylated form and plays a critical role in regulating the process of melanin biosynthesis (also known … [A231829, A231839] It is recognized as being the main enzyme responsible for enzymatic browning and melanogenesis in mammals, thus causing undesired browning of fruits and vegetables and diseases resulting

  4. Drug

    Rilmenidine

    go.drugbank.com/drugs/DB11738
    ApprovedWithdrawn

    Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.

  5. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies). Amredobresib has a monoisotopic molecular weight of 467.25 Da. … The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

  6. Drug

    Tegtociclib

    go.drugbank.com/drugs/DB21635
    Investigational

    Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid … Tegtociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor.

  7. Drug

    Felezonexor

    go.drugbank.com/drugs/DB21067
    Investigational

    Felezonexor is under investigation in clinical trial NCT02667873 (A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors). … Felezonexor is a small molecule drug. The usage of the INN stem '-nexor' in the name indicates that Felezonexor is a nuclear export inhibitor.

  8. Drug

    Telenzepine

    go.drugbank.com/drugs/DB19508
    Investigational

    Telenzepine is a small molecule drug. The usage of the INN stem '-zepine' in the name indicates that Telenzepine is a tricyclic compound. … Telenzepine is under investigation in clinical trial NCT01155531 (Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects).

  9. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton is under investigation in clinical trial NCT00404313 (The Effect of MK0633 in Patients With Chronic Asthma (0633-007)). Setileuton has a monoisotopic molecular weight of 463.12 Da. … Setileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.

  10. Drug

    Icovamenib

    go.drugbank.com/drugs/DB21669
    Investigational

    Icovamenib is a small molecule drug. The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor. … Icovamenib is under investigation in clinical trial NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus). Icovamenib has a monoisotopic molecular weight of 566.28 Da.